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Abstract
Background: Despite common enthusiasm for cardiovascular magnetic resonance (CMR), its application in Europe
is quite diverse. Restrictions are attributed to a number of factors, like limited access, deficits in training, and incomplete
reimbursement. Aim of this study is to perform a systematic summary of the representation of CMR in the guidelines
of the European Society of Cardiology (ESC).
Methods: Twenty-nine ESC guidelines were screened for the terms “magnetic”, “MRI”, “CMR”, “MR” and “imaging”. As 3
topics were published twice (endocarditis, pulmonary hypertension, NSTEMI), 26 guidelines were finally included. MRI
in the context of non-cardiovascular examinations was not recognized. The main CMR-related conclusions and, if
available, the level of evidence and the class of recommendation were extracted.
Results: Fourteen of the 26 guidelines (53.8 %) contain specific recommendations regarding the use of CMR.
Nine guidelines (34.6 %) mention CMR in the text, and 3 (11.5 %) do not mention CMR. The 14 guidelines with
recommendations regarding the use of CMR contain 39 class-I recommendations, 12 class-IIa recommendations,
10 class-IIb recommendations and 2 class-III recommendations. Most of the recommendations have evidence
level C (41/63; 65.1 %), followed by level B (16/63; 25.4 %) and level A (6/63; 9.5 %). The four guidelines, which
absolutely contained most recommendations for CMR, were stable coronary artery disease (n = 14), aortic diseases
(n = 9), HCM (n = 7) and myocardial revascularization (n = 7).
Conclusions: CMR is represented in the majority of the ESC guidelines. They contain many recommendations in
favour of the use of CMR in specific scenarios. Issues regarding access, training and reimbursement have to be
solved to offer CMR to patients in accordance with the ESC guidelines.
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Background
Cardiovascular magnetic resonance (CMR) has been ap-
plied in a wide variety of indications in clinical cardi-
ology. The most frequent indications are inflammatory
and ischemic heart disease as well as cardiomyopathies.
But also in rare diseases like amyloidosis, as well as in
congenital heart disease, CMR has demonstrated its use-
fulness [1, 2]. CMR provides detailed information about
cardiovascular anatomy and function by combining di-
verse techniques. In particular, the characterization of
the myocardial tissue including the detection of oedema
and the highly resolved determination of fibrosis is a
unique feature of CMR [3]. Furthermore, with myocar-
dial stress-perfusion imaging – free of ionizing radiation
and with high diagnostic accuracy – the large patient
group with (suspected) coronary artery disease is ad-
dressed [4]. Finally, the introduction of robust and fast
imaging techniques as well as targeted examination pro-
tocols facilitated the clinical use [5].
Despite common enthusiasm for this modality, its
use in Europe is quite diverse. This restriction is
attributed to a number of factors, like missing skills
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both to run a CMR examination and to interpret the
images under integration of profound cardiologic
knowledge; relatively high costs and incomplete reim-
bursement; and limited access to scanners with cardiac
dedication.
Aim of this study is to perform a systematic sum-
mary of the representation of CMR in the guidelines
of the European Society of Cardiology (ESC) in order
to stimulate the discussion about future plans for
training, distribution and reimbursement of CMR in
Europe.
Methods
All ESC guidelines, which are listed on the ESC website
(http://www.escardio.org/Guidelines-&-Education/Clinical-
Practice-Guidelines/ESC-Clinical-Practice-Guidelines-list/
listing) were collected (Table 1). If more than one guide-
line for the same topic has been published in this period,
both were analysed for changes, but only the most recent
was included in the final analysis. The documents were
screened for the terms “magnetic”, “MRI”, “CMR”, “MR”
and “imaging”. MRI in the context of non-cardiovascular
examinations like brain MRI was not recognized. The main
Table 1 List of ESC guidelines used for this summary. 1 = guideline contains specific recommendations regarding the use of CMR;
2 = guideline mentions scenarios in which CMR may be used, but without giving any specific recommendation; 3 = guideline does
not mention CMR at all
Nr. Title Year Role of CMR
1 ESC Guidelines for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death [6]
2015 1
2 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension [7] 2015 2
3 ESC guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation [9]
2015 1
4 ESC Guidelines for the diagnosis and management of pericardial diseases [11] 2015 1
5 ESC Guidelines for the management of infective endocarditis [12] 2015 1
6 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy [14] 2014 1
7 ESC Guidelines on the diagnosis and treatment of aortic diseases [15] 2014 1
8 ESC/EACTS Guidelines on myocardial revascularization [16] 2014 1
9 ESC Guidelines on the diagnosis and management of acute pulmonary embolism [17] 2014 1
10 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management [18] 2014 1
11 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in
collaboration with the EASD [19]
2013 2
12 ESC guidelines on the management of stable coronary artery disease [20] 2013 1
13 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy [21] 2013 2
14 ESH/ESC Guidelines for the management of arterial hypertension [22] 2013 1
15 ESC/EACTS Guidelines on the management of valvular heart disease [23] 2012 2
16 Focused update of the ESC Guidelines for the management of atrial fibrillation [24] 2012 3
17 ESC/ACCF/AHA/WHF Third universal definition of myocardial infarction [25] 2012 2
18 ESC Guidelines for the management of acute myocardial infarction in patients presenting
with ST-segment elevation [26]
2012 1
19 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [27] 2012 1
20 European Guidelines on cardiovascular disease prevention in clinical practice [28] 2012 2
21 ESC/EAS Guidelines for the management of dyslipidaemias [29] 2011 3
22 ESC Guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation [10]
2011 (new guideline 2015)
23 ESC Guidelines on the management of cardiovascular diseases during pregnancy [30] 2011 1
24 ESC Guidelines on the diagnosis and treatment of peripheral artery diseases [31] 2011 1
25 ESC Guidelines for the management of grown-up congenital heart disease [32] 2010 2
26 Focused Update of ESC Guidelines on device therapy in heart failure [34] 2010 3
27 Guidelines on the prevention, diagnosis, and treatment of infective endocarditis [23] 2009 (new guideline 2015)
28 Guidelines for the diagnosis and management of syncope [35] 2009 2
29 Guidelines for the diagnosis and treatment of pulmonary hypertension [8] 2009 (new guideline 2015)
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conclusions were extracted and if available, the level of
evidence and the class of recommendation were given
(Tables 2 and 3). The number in parenthesis behind the
citation provides the page of the fulltext guideline. If a rec-
ommendation refers to “imaging” in general, it was regis-
tered if the context included CMR. This process was done
twice for every guideline to reassure that no relevant
information was missed. The absolute number of recom-
mendations is finally summarized, whereby equal recom-
mendations that appeared in more than one guideline
were only counted once. The order of the guidelines is
chronologic beginning with the most recent. Guidelines
other than by the ESC as well as ESC position statements
were not included to guarantee one common level of
guideline.
Results
Of the 29 ESC guidelines we screened, three topics were
covered twice (endocarditis 2015 and 2009, pulmonary
hypertension 2015 and 2009, NSTEMI 2015 and 2011).
Of the remaining 26 ESC guidelines, 14 (53.8 %) contain
specific recommendations regarding the use of CMR
(Fig. 1, Table 1). Nine guidelines (34.6 %; endocarditis, pul-
monary hypertension, diabetes, pacing, heart valve disease,
definition of infarction, prevention, congenital heart dis-
ease, syncope) principally mention scenarios in which
CMR may be used, but without giving any specific recom-
mendation. Three guidelines (11.5 %; atrial fibrillation,
dyslipidaemias, device therapy in heart failure) do not
mention CMR at all. The 14 guidelines with recommenda-
tions regarding the use of CMR contain 39 class-I recom-
mendations, 12 class-IIa recommendations, 10 class-IIb
recommendations and 2 class-III recommendations
(Fig. 2). (The diverse recommendations for myocardial
revascularization in dependency of the evidence of ische-
mia were only counted once as IA). Most of the recom-
mendations have evidence level C (41/63; 65.1 %),
followed by level B (16/63; 25.4 %) and level A (6/63;
9.5 %). The two class-III recommendations in the context
of CMR are: i) In the guideline for pulmonary embolism,
MR angiography should not be used to rule out pulmon-
ary embolism. ii) In the guideline about assessment before
non-cardiac surgery, imaging stress testing in general is
not recommended before low-risk surgery. The four
guidelines, which absolutely contained most recommen-
dations with referral to CMR, were stable coronary artery
disease from 2013 (n = 14), aortic diseases (n = 9), HCM
(n = 7) as well as myocardial revascularization (n = 7) from
2014. Twenty-eight recommendations refer to stress-
imaging, 17 recommendations refer to the vasculature, 7
to cardiomyopathies, 5 to left- and right-ventricular
function assessment (in part including fibrosis im-
aging), 4 to the pericardium and 2 to myocarditis. A
summary of clinical scenarios/diagnoses, where the
ESC made recommendations regarding CMR, is pro-
vided in the appendix of this paper.
2015 ESC guidelines for the management of patients with
ventricular arrhythmias and the prevention of sudden
cardiac death [6]
Table 4 summarizes the recommendations for CMR in
the context of patients with ventricular arrhythmias and
the prevention of sudden cardiac death.
For family members of sudden unexplained death syn-
drome or sudden arrhythmic death syndrome victims,
echocardiography and/or CMR is recommended (Ap-
pendix on page 11 of the guideline). In patients with sus-
tained ventricular tachycardia or ventricular fibrillation,
the recommended algorithm for further patient assess-
ment includes CMR (Fig. 1 on page 14). For instance
myocarditis should also be suspected and a CMR scan
may reveal abnormal fibrotic myocardial tissue (page
54). In patients with non-ischaemic cardiomyopathy,
CMR fibrosis imaging (using late gadolinium enhance-
ment, LGE) is associated with increased risk of all-cause
mortality, heart failure hospitalization and sudden
Table 2 Class of recommendations
Class of recommendation Definition Suggested wording to use
Class I Evidence and/or general agreement that a given treatment or procedure is beneficial,
useful, effective.
Is recommended/is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of
the given treatment or procedure.
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion. May be considered
Class III Evidence or general agreement that the given treatment or procedure is not useful/
effective, and in some cases may be harmful.
Is not recommended
Table 3 Level of evidence
Level of evidence A Data derived from multiple randomized clinical
trials or meta-analyses.
Level of evidence B Data derived from a single randomized clinical
trial or large non-randomized studies.
Level of evidence C Consensus of opinion of the experts and/or
small studies, retrospective studies, registries.
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cardiac death. The incremental value of LGE over other
prognostic markers needs to be determined (page 36).
Standardized evaluation of patients with HCM should
include CMR in the case of inadequate echo window
(page 39). LGE has been suggested to be used to guide
ICD therapy in individuals with HCM with intermediate
risk, however with few supportive data (page 38). Simi-
larly, LGE on CMR of the right and left ventricle has
been reported as risk factors for sudden cardiac death or
appropriate ICD discharge in ARVC (page 40). In par-
ticular in ARVC, CMR provides excellent assessment of
right ventricular size, function and regional wall motion.
In paediatric patients with frequent premature ventricu-
lar complexes, cardiac evaluation including CMR is rec-
ommended (page 46). Non-invasive imaging of cardiac
structure, best done by CMR, can be used to plan and
guide ablation procedures for ventricular tachycardia
(page 22).
2015 ESC/ERS guidelines for the diagnosis and treatment
of pulmonary hypertension [7]
CMR is listed among the tests to contribute to the
diagnosis of pulmonary hypertension, being accurate
and reproducible in the assessment of right ventricu-
lar size, morphology and function and of blood flow,
stroke volume, cardiac output, pulmonary arterial
distensibility and right ventricular mass. The pres-
ence of LGE, reduced pulmonary arterial distensibil-
ity and retrograde flow have high predictive value for
the identification of pulmonary hypertension. In pa-
tients with pulmonary hypertension, CMR may also
be useful in cases of suspected congenital heart dis-
ease if echocardiography is not conclusive. MR angi-
ography has a potential in patients with suspected
chronic thromboembolic pulmonary hypertension.
CMR provides useful prognostic information in pa-
tients with pulmonary artery hypertension (page 12).
Fig. 1 Left: Number of ESC guidelines screened for this analysis per year. Right: Number of specific recommendations regarding CMR per year
Fig. 2 Class and level of the recommendations for CMR in the ESC guidelines
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Specifically, right atrial size and the presence of peri-
cardial effusion as assessed by CMR are used for risk
assessment in pulmonary arterial hypertension (table
13 of the guideline). There is no specific recommen-
dation regarding CMR and no significant change
regarding the role of CMR in pulmonary hyperten-
sion between the present guideline and the 2009
version [8].
2015 ESC guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-
segment elevation [9]
CMR can assess both perfusion and wall motion abnormal-
ities, and patients presenting with acute chest pain with a
normal stress CMR have an excellent short- and midterm
prognosis. CMR also permits detection of scar tissue and
can differentiate this from recent infarction. CMR can facili-
tate the differential diagnosis between infarction and myo-
carditis or Tako-Tsubo cardiomyopathy (page 11). In
subjects with no criteria for early invasive strategy, a non-
invasive imaging stress test is recommended. No specific test
is mentioned (Table 5). There is no significant change of the
role of CMR compared to the 2011 NSTEMI guideline [10].
2015 ESC guidelines for the diagnosis and management
of pericardial diseases [11]
CMR has shifted towards a comprehensive imaging mo-
dality, allowing visualization and tissue characterization
of the pericardium (and heart) in patients with pericar-
dial disease and appraisal of the consequences of peri-
cardial abnormalities on cardiac function and filling
patterns (page 20). Table 12 of the guideline summa-
rizes the contribution of different imaging modalities in
various pericardial diseases and table 13 of the guideline
compares non-invasive imaging modalities to study the
pericardium. Thereby, CMR is predominantly ranked as
good (“++”) or excellent (“+++”). Under the headline
“what is new”, CMR is recommended for the detection
of pericardial inflammation to identify forms of initial
reversible constrictive pericarditis, allowing a trial of
medical anti-inflammatory therapy (page 5). The evi-
dence of pericardial inflammation by CMR is also men-
tioned as one diagnostic criterion for acute pericarditis
(table 4 of the guideline). In patients with myocarditis,
CMR is recommended for the confirmation of myocar-
dial involvement (page 13). CMR may be helpful to de-
tect loculated pericardial effusion and pericardial
thickening and masses, as well as associated chest ab-
normalities. CMR can contribute to the differentiation
of constrictive pericarditis and restrictive cardiomyop-
athy (table 10 of the guideline), e.g. by assessment of
ventricular coupling with real-time cine magnetic res-
onance during free breathing (page 19). In some cases
of pericardial cysts, CMR may be helpful (page 35). The
recommendations made for CMR in pericardial diseases
are summarized in Table 6.
Table 4 Recommendations for CMR in patients with ventricular arrhythmias and for the prevention of sudden cardiac death
Non-invasive evaluation of patients with suspected or known ventricular arrhythmias Classa Levelb Page
Pharmacological stress testing plus imaging modality is recommended to detect silent ischaemia in patients with ventricular
arrhythmias who have an intermediate probability of having coronary artery disease by age or symptoms and are physically
unable to perform a symptom-limited exercise test.
I B 12
CMR or CT should be considered in patients with ventricular arrhythmias when echocardiography does not provide accurate
assessment of LV and RV function and/or evaluation of structural changes.
IIa B 12
Management of ventricular arrhythmias in inflammatory heart disease Classa Levelb Page
Demonstration of persistent myocardial inflammatory infiltrates by immunohistological evidence and/or abnormal localized
fibrosis by CMR after acute myocarditis may be considered as an additional indicator of increased risk of SCD in inflammatory
heart disease.
IIb C 53
Prevention of sudden cardiac death in athletes Classa Levelb Page
Upon identification of ECG abnormalities suggestive of structural heart disease, echocardiography and/or CMR imaging is
recommended.
I C 62
a Class of recommendation
b Level of evidence
Table 5 Recommendations for imaging in patients with suspected non-ST-elevation acute coronary syndromes
Recommendations for imaging in patients with suspected non-ST-elevation acute coronary syndromes Classa Levelb Page
In patients with no recurrence of chest pain, normal ECG findings and normal levels of cardiac troponin (preferably high-
sensitivity), but suspected acute coronary syndrome, a non-invasive stress test (preferably with imaging) for inducible ischaemia
is recommended before deciding on an invasive strategy.
I A 15
a Class of recommendation
b Level of evidence
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2015 ESC guidelines for the management of infective
endocarditis [12]
Within the subchapter about ‘complications of infective
endocarditis’ dealing with ‘myocarditis and pericarditis’,
CMR is mentioned (next to echocardiography) to assess
myocardial involvement during infective endocarditis (page
30). This CMR indication is new compared to the 2009
guideline [13].
2014 ESC guidelines on diagnosis and management of
hypertrophic cardiomyopathy [14]
HCM in adults is defined by a wall thickness
≥15 mm and in first-degree relatives ≥13 mm in one
or more LV myocardial segments - as measured by
any imaging technique, including CMR (page 7, 8).
Some patients with apical or distal hypertrophy de-
velop small apical aneurysms, sometimes associated
with myocardial scarring. These may only be detect-
able on CMR, ventriculography or contrast echo
(page 9). The prevalence of non-sustained ventricular
tachycardia increases with age and correlates with LV
wall thickness and the presence of LGE on CMR
(page 36). However, even though the extent of LGE
on CMR has some utility in predicting cardiovascular
mortality, current data do not support the use of
LGE in prediction of sudden cardiac death risk (page
14). LGE at the right ventricular insertion points or
localized to segments of maximum LV thickening on
CMR assists for differentiating the diagnosis of hyper-
tensive heart disease and HCM (table 9 of the guide-
line). The specific recommendations made for CMR
in HCM are summarized in Table 7.
2014 ESC guidelines on the diagnosis and treatment of
aortic diseases [15]
CMR is regarded as a valuable tool to image the aorta. On a
scale from “+” to “+++”, the ease of use is graded as “++”,
diagnostic reliability as “+++”, serial examinations as “+++”,
and aortic wall visualization as “+++” (page 11). CMR is con-
sidered the leading technique for diagnosis of aortic dissec-
tion, with a reported sensitivity and specificity of 98 %.
However, several methodological and practical limitations
preclude the use of this modality in the majority of cases and
in unstable patients (page 21). Recommendations for the use
of CMR in patients with aortic diseases are given Table 8.
2014 ESC/EACTS guidelines on myocardial
revascularization [16]
This guideline contains recommendations for CMR both for
determining myocardial ischemia and for follow-up patients
after myocardial revascularization, as well as for preparation
before surgical myocardial revascularization. Table 9 shows
the specific recommendations. There is no clear recommen-
dation for CMR viability testing. Even though CMR has a
high diagnostic accuracy for assessing the transmural extent
of myocardial scar tissue and contractile reserve, its ability
to detect viability and predict recovery of wall motion is no
better than other imaging techniques (page 15).
2014 ESC guidelines on the diagnosis and management
of acute pulmonary embolism [17]
MR angiography, although promising, is not yet ready
for clinical practice due to its low sensitivity, high pro-
portion of inconclusive MR angiography scans, and low
availability in most emergency settings (Table 10).
Table 6 Recommendations for CMR in pericardial diseases
Recommendation for diagnostic work-up of pericardial diseases Classa Levelb Page
CT and/or CMR are second-level testing for diagnostic workup in pericarditis I C 38
Recommendations for the diagnosis and management of pericarditis associated with myocarditis Classa Levelb Page
CMR is recommended for the confirmation of myocardial involvement I C 13
Recommendations for the diagnosis of pericardial effusion Classa Levelb Page
CT or CMR should be considered in suspected cases of loculated pericardial effusion, pericardial thickening and masses, as
well as associated chest abnormalities
IIa C 14
Recommendations for the diagnosis of constrictive pericarditis Classa Levelb Page
CT and/or CMR are indicated as second-level imaging techniques to assess calcifications (CT), pericardial thickness, degree
and extension of pericardial involvement
I C 17
Recommendations for therapy of constrictive pericarditis Classa Levelb Page
Empiric anti-inflammatory therapy may be considered in cases with transient or new diagnosis of constriction with concomitant
evidence of pericardial inflammation (i.e. CRP elevation or pericardial enhancement on CT/CMR)
IIb C 19
a Class of recommendation
b Level of evidence
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2014 ESC/ESA guidelines on non-cardiac surgery:
cardiovascular assessment and management [18]
Resting LV function can be evaluated before non-cardiac
surgery in high-risk surgery (IIb, C). Following the guide-
lines, this can be done by radionuclide ventriculography,
gated single photon emission computed tomography, echo-
cardiography, CMR or multislice CT all with similar accur-
acy. The recommendations for non-invasive stress testing
of ischemic heart disease are given in Table 11. As nuclear
myocardial perfusion imaging and stress echocardiography
were mainly used in clinical studies about preoperative is-
chemic testing, these modalities are pronounced. CMR
(both perfusion and wall motion analysis) is mentioned as
an accurate alternative method.
2013 ESC guidelines on diabetes, pre-diabetes, and
cardiovascular diseases developed in collaboration with
the EASD [19]
Patients with glucose perturbations are in need of
early risk assessment to identify co-morbidities and
factors that increase cardiovascular risk. This includes
among other the evaluation of myocardial viability
and LV function by means of echo-Doppler and/or
CMR (page 28), and Duplex ultrasonography, com-
puted tomography angiography and CMR to evaluate
carotid artery stenosis (page 45). To evaluate indu-
cible ischaemia, only exercise testing, stress echocar-
diography, or myocardial scintigraphy are mentioned
(page 28).
Table 7 Recommendations for CMR in patients with HCM
Recommendations for CMR in patients with HCM Classa Levelb Page
It is recommended that CMR studies be performed and interpreted by teams experienced in cardiac imaging and in the
evaluation of heart muscle disease
I B 14
In the absence of contraindications, CMR with LGE is recommended in patients with suspected HCM who have inadequate
echocardiographic windows, in order to confirm the diagnosis.
I C 14
In the absence of contraindications, CMR with LGE should be considered in patients fulfilling diagnostic criteria for HCM, to
assess cardiac anatomy, ventricular function, and the presence and extent of myocardial fibrosis.
IIa B 14
CMR with LGE imaging should be considered in patients with suspected apical hypertrophy or aneurysm. IIa C 14
CMR with LGE imaging should be considered in patients with suspected cardiac amyloidosis. IIa C 14
CMR with LGE may be considered before septal alcohol ablation or myectomy, to assess the extent and distribution of
hypertrophy and myocardial fibrosis.
IIb C 14
CMR may be considered every 5 years in clinically stable patients, or every 2–3 years in patients with progressive disease. IIb C 37
a Class of recommendation
b Level of evidence
Table 8 Recommendations for CMR in aortic diseases
Recommendations on diagnostic work-up of acute aortic syndrome Classa Levelb Page
In stable patients with a suspicion of acute aortic syndrome, CMR is recommended (or should be considered) according to
local availability and expertise
I C 22
In case of initially negative imaging with persistence of suspicion of acute aortic syndrome, repetitive imaging (CT or CMR) is
recommended.
I C 22
In case of uncomplicated Type B aortic dissection treated medically, repeated imaging (CT or CMR) during the first days is
recommended.
I C 22
In uncomplicated Type B intramural hematoma, repetitive imaging (CMR or CT) is indicated. I C 26
In uncomplicated Type B penetrating aortic ulcer, repetitive imaging (CMR or CT) is indicated. I C 27
Recommendations for the management of aortic root dilation in patients with bicuspid aortic valve Classa Levelb Page
CMR or CT is indicated in patients with bicuspid aortic valve when the morphology of the aortic root and the ascending
aorta cannot be accurately assessed by TTE.
I C 42
In the case of aortic diameter >50 mm or an increase >3 mm/year measured by echocardiography, confirmation of the
measurement is indicated, using another imaging modality (CT or CMR).
I C 42
Recommendations for follow-up and management in chronic aortic diseases Classa Levelb Page
Contrast CT or CMR is recommended to confirm the diagnosis of chronic aortic dissection. I C 48
For follow-up after (T)EVAR in young patients, CMR should be preferred to CT for magnetic resonance-compatible stent
grafts, to reduce radiation exposure.
IIa C 48
a Class of recommendation
b Level of evidence
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2013 ESC guidelines on the management of stable
coronary artery disease [20]
Table 12 summarizes the corresponding recommenda-
tions for CMR in the context of stable coronary artery
disease. CMR may be used to define structural cardiac
abnormalities and evaluate ventricular function. Use of
CMR is recommended in patients, in whom, despite the
use of echo contrast agents, transthoracic echocardiog-
raphy is unable to answer the clinical question (usually
because of a restricted acoustic window) and who have
no contra-indications for CMR (page 13). In patients
with suspected coronary artery disease and intermediate
pretest probability, non-invasive testing is recom-
mended. Among the modalities to perform stress im-
aging, CMR is mentioned on the same level as stress
echocardiography, SPECT and PET. To stratify the risk
for events, high risk is assumed in stress CMR if there
are ≥2/16 segments with new perfusion defects or ≥3
dobutamine-induced dysfunctional segments (page 20).
CMR coronary arteriography must still be regarded
primarily as a research tool and is not recommended for
routine clinical practice in the diagnostic evaluation of
suspected coronary artery disease (page 19).
2013 ESC guidelines on cardiac pacing and cardiac
resynchronization therapy [21]
Regarding patient selection for cardiac resynchronization
therapy, it is mentioned that CMR and other imaging
techniques were evaluated. However, the real value of
these novel technologies remains to be determined in
randomized trials (page 23). Furthermore, general safety-
based recommendations for MR imaging in patients with
implanted cardiac devices are given, according to con-
ventional or MR-conditional devices (page 44).
2013 ESH/ESC guidelines for the management of arterial
hypertension [22]
When searching for asymptomatic organ damage in patients
with arterial hypertension, CMR should be considered for as-
sessment of LV size and mass when echocardiography is
Table 9 Recommendations for CMR in the context of myocardial revascularization
Recommendations for imaging to determine ischemia to plan revascularization Classa Levelb Page
Stress CMR, stress-echo, SPECT or PET are recommended in subjects with intermediate pretest probability for suspected
coronary artery disease and stable symptoms
I A 14
To achieve a prognostic benefit by revascularization in patients with coronary artery disease, ischemia has to be
documented by non-invasive imaging
Left main disease with stenosis >50 % I A 18
Any proximal LAD stenosis >50 % I A 18
Two-vessel or three-vessel disease with stenosis > 50 % with impaired LV function (LVEF < 40 %)a I A 18
Large area of ischaemia (>10 % LV) I B 18
Single remaining patent coronary artery with stenosis >50 % I C 18
Recommendations for follow-up and management after myocardial revascularization for asymptomatic patients Classa Levelb Page
Early imaging testing should be considered in specific patient subsets. IIa C 72
Routine stress testing may be considered >2 years after PCI and >5 years after CABG. IIa B 72
Recommendations for follow-up and management after myocardial revascularization for symptomatic patients Classa Levelb Page
It is recommended to reinforce medical therapy and lifestyle changes in patients with low-risk findings at stress testing. I C 72
With intermediate- to high-risk findings at stress testing, coronary angiography is recommended. I C 72
Recommendation for carotid artery screening before CABG Classa Levelb Page
CMR, CT, or digital subtraction angiography may be considered if carotid artery stenosis by ultrasound is >70 % and
myocardial revascularization is contemplated.
IIb C 39
a Class of recommendation
b Level of evidence
Table 10 Recommendation for CMR in pulmonary embolism
Recommendations for CMR in pulmonary embolism Classa Levelb Page
MR angiography should not be used to rule out pulmonary embolism. III C 11
a Class of recommendation
b Level of evidence
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technically not feasible and when LGE imaging would
have therapeutic consequences (page 17). On a scale
from “+” to “++++”, CMR was graded with “++” re-
garding cardiovascular predictive value, “+” regarding
availability, “+++” regarding reproducibility” and “++”
regarding cost-effectiveness (page 20). CMR is rated
as highly sensitive to detect changes of LV
hypertrophy, superior to echocardiography and ECG
(page 51). Concerning renal artery stenosis as cause
of secondary hypertension, CMR is named as add-
itional/confirmatory test after renal ultrasonography
(page 22). The recommendation for CMR in suspected
ischemic heart disease in the context of hypertension-
induced organ damage is given in Table 13.
Table 11 Recommendations for CMR in the context of non-cardiac surgery
Recommendations for non-invasive stress testing of ischemic heart disease Classa Levelb Page
Imaging stress testing is recommended before high-risk surgery in patients with more than two clinical risk factors and poor
functional capacity (<4 METs).
I C 12
Imaging stress testing may be considered before high- or intermediate-risk surgery in patients with one or two clinical risk
factors and poor functional capacity (<4 METs).
IIb C 12
Imaging stress testing is not recommended before low-risk surgery, regardless of the patient’s clinical risk. III C 12
a Class of recommendation
b Level of evidence
Table 12 Recommendations for CMR in stable coronary artery disease
Recommendations for non-invasive testing for ischemic heart disease Classa Levelb Page
In patients with suspected stable coronary artery disease and intermediate pretest probability of 15 % - 65 % and LVEF
≥50 %, stress imaging is preferred as the initial test option if local expertise and availability permit.
I B 17
An imaging stress test is recommended as the initial test for diagnosing stable coronary artery disease if the pretest
probability is between 66-85 % or if LVEF is <50 % in patients without typical angina.
I B 17
An imaging stress test is recommended in patients with resting ECG abnormalities, which prevent accurate interpretation of
ECG changes during stress.
I B 17
An imaging stress test should be considered in symptomatic patients with prior revascularization (PCI or CABG). IIa B 17
An imaging stress test should be considered to assess the functional severity of intermediate lesions on coronary
arteriography.
IIa B 17
Recommendations for risk stratification using ischemia testing Classa Levelb Page
Risk stratification is recommended based on clinical assessment and the results of the stress test initially employed for
making a diagnosis of stable coronary artery disease
I B 22
Stress imaging for risk stratification is recommended in patients with a non-conclusive exercise ECG I B 22
Risk stratification using stress ECG (unless they cannot exercise or display ECG changes which make the ECG non evaluable)
or preferably stress imaging if local expertise and availability permit is recommended in patients with stable coronary disease
after a significant change in symptom level
I B 22
Stress imaging is recommended for risk stratification in patients with known stable coronary artery disease and a
deterioration in symptoms if the site and extent of ischemia would influence clinical decision making
I B 22
In asymptomatic adults with diabetes or asymptomatic adults with a strong family history of coronary artery disease or
when previous risk assessment testing suggests high risk of coronary artery disease, such as a coronary artery calcium score
of 400 or greater stress imaging tests (MPI, stress echocardiography, perfusion CMR) may be considered for advanced
cardiovascular risk assessment.
IIb C 24
Recommendation for re-assessment in patients with stable coronary artery disease Classa Levelb Page
An exercise ECG or stress imaging if appropriate is recommended in the presence of recurrent or new symptoms once
instability has been ruled out.
I C 25
Reassessment of the prognosis using stress testing may be considered in asymptomatic patients after the expiration of the
period for which the previous test was felt to be valid (“warranty period”)
IIb C 25
In symptomatic patients with revascularized stable coronary artery disease, stress imaging (stress echocardiography, CMR or
MPS) is indicated rather than stress ECG.
I C 47
Late (6 months) stress imaging test after revascularization may be considered to detect patients with restenosis after
stenting or graft occlusion irrespective of symptoms.
IIb C 47
a Class of recommendation
b Level of evidence
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2012 guidelines on the management of valvular heart
disease [23]
In patients with inadequate echocardiographic quality or
discrepant results, CMR should be used to assess the se-
verity of valvular lesions - particularly regurgitant lesions -
and to assess ventricular volumes and systolic function, as
CMR assesses these parameters with higher reproducibil-
ity than echocardiography. CMR is the reference method
for the evaluation of right ventricular volumes and func-
tion and is therefore useful to evaluate the consequences
of tricuspid regurgitation. In practice, the routine use of
CMR is limited because of its limited availability, com-
pared with echocardiography (page 7).
In aortic regurgitation, CMR (or CT) is recommended
for the evaluation of the aorta in patients with Marfan
syndrome, or if an enlarged aorta is detected by echocardi-
ography, particularly in patients with bicuspid aortic
valves (page 10). Furthermore, CT or preferably CMR are
advisable when the distal ascending aorta is not well visu-
alized and/or when the surgical indication may be based
on aortic enlargement, rather than LV size or function.
In aortic stenosis with paradoxical low flow, the diag-
nosis of severe AS requires careful exclusion of diverse
reasons for the echo constellation before making the de-
cision to intervene. In addition to more detailed echo-
cardiographic measurements, this may require CMR and
catheterization (page 14). (CT and) CMR provide add-
itional information on the assessment of the ascending
aorta when it is enlarged (page 14). Furthermore, CMR
may also be useful for the detection and quantification
of myocardial fibrosis, providing additional prognostic
information in symptomatic patients without coronary
artery disease (page 14).
In secondary mitral regurgitation and low LVEF, it is
also mandatory to assess the absence, or presence and ex-
tent, of myocardial viability by one of the available im-
aging techniques (dobutamine echocardiography, SPECT,
PET or CMR) (page 23). There are no specific recommen-
dations for CMR in this guideline.
2012 focused update of the ESC Guidelines for the
management of atrial fibrillation [24]
CMR is not mentioned in this guideline.
2012 third universal definition of myocardial infarction [25]
Imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality is listed among the
criteria for acute myocardial infarction. Among the cri-
teria for prior myocardial infarction, imaging evidence of a
region of loss of viable myocardium that is thinned and
fails to contract, in the absence of a non-ischaemic cause,
is listed (page 3). CMR is mentioned next to other imaging
tests (page 9) for assessing myocardial viability, perfusion,
and function. Furthermore, its value in detecting myocar-
dial disease states that can mimic myocardial infarct, such
as myocarditis, is emphasized (page 10). There are no spe-
cific recommendations for CMR in this guideline.
2012 ESC guidelines for the management of acute
myocardial infarction in patients presenting with
ST-segment elevation [26]
Contrast-enhanced CMR is mentioned as one of several
techniques to make the diagnosis of no-reflow. If, in
spite of the angiography performed in the acute phase,
there are concerns about inducible ischaemia, an out-
patient exercise-testing or stress-imaging test (using
scintigraphy, echocardiography or CMR) is appropriate.
Regarding the assessment of viability, the same state-
ment as within the revascularization guidelines from
2014 is given: CMR has a high diagnostic accuracy for
assessing transmural extent of myocardial scar tissue,
but its ability to detect viability and predict recovery of
wall motion is not superior to other imaging techniques
Table 13 Recommendation for CMR in the management of arterial hypertension
Recommendations for stress-testing in arterial hypertension Classa Levelb Page
Whenever history suggests myocardial ischaemia, a stress ECG test is recommended, and, if positive or ambiguous, an imaging
stress test (stress echocardiography, stress CMR or nuclear scintigraphy) is recommended.
I C 21
a Class of recommendation
b Level of evidence
Table 14 Recommendations for CMR in patients with STEMI
Recommendations for imaging during hospitalization and at discharge in patients with STEMI Classa Levelb Page
If echocardiography is not feasible, CMR may be used as an alternative for assessment of infarct size and resting LV function. IIb C 26
For patients with multivessel disease, or in whom revascularization of other vessels is considered, stress testing or imaging (e.g.
using stress myocardial perfusion scintigraphy, stress echocardiography, positron emission tomography or CMR) for ischaemia
and viability is indicated before or after discharge.
I A 26
a Class of recommendation
b Level of evidence
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(page 27). Table 14 shows the recommendations for
CMR in patients with STEMI.
2012 ESC guidelines for the diagnosis and treatment of
acute and chronic heart failure [27]
CMR is particularly valuable in identifying inflammatory
and infiltrative conditions as well as in the work-up of
patients with suspected cardiomyopathy, arrhythmias,
suspected cardiac tumours, or pericardial diseases, and
is the imaging method of choice in patients with com-
plex congenital heart disease (pages 16–17). Table 7 of
the guideline summarizes possible applications of vari-
ous imaging techniques in the diagnosis of heart failure.
Thereby, the value of CMR is rated - on a scale from “+”
to “+++” - with “+++” regarding coronary artery disease,
myocarditis, sarcoidosis, amyloidosis, eosinophilic syn-
dromes, iron overload, arrhythmogenic right ventricular
cardiomyopathy, endomyocardial fibrosis; with “++” re-
garding valvular regurgitation, HCM, pericarditis,
Takotsubo-cardiomyopathy, and with “+” regarding
valvular stenosis and Anderson-Fabry-Disease. In pa-
tients presenting with heart failure and ECG signs of LV
hypertrophy or low QRS voltage, CMR is recommended
for further work-up. Table 15 provides recommendations
for CMR in ambulatory patients suspected of having
heart failure.
2012 European guidelines on cardiovascular disease
prevention in clinical practice [28]
This guideline dedicates a chapter to the early detection
of cardiovascular disease in asymptomatic subjects by
CMR. It concludes that at present, CMR is a promising
research tool, but its routine use remains limited and it
is not yet appropriate for identifying patients at high risk
for cardiovascular disease (page 23).
2011 ESC/EAS guidelines for the management of
dyslipidaemias [29]
This guideline does not contain relevant paragraphs re-
garding CMR.
2011 ESC guidelines on the management of
cardiovascular diseases during pregnancy [30]
CMR may be useful in diagnosing complex heart disease
or pathology of the aorta. Limited data during organo-
genesis are available, but CMR is probably safe, espe-
cially after the first trimester. Gadolinium can be
assumed to cross the fetal blood-placental barrier, but
data are limited. The long-term risks of exposure of the
developing fetus to free gadolinium ions are not known,
and therefore gadolinium should be avoided (page 8). In
bicuspid aortic valve disease, dilatation is often maximal
in the distal part of the ascending aorta, which cannot
be adequately visualized echocardiographically; there-
fore, CMR or CT should be performed before pre-
pregnancy (page 21). Table 16 summarizes recommenda-
tions for CMR during pregnancy.
2011 ESC guidelines on the diagnosis and treatment of
peripheral artery diseases [31]
MR angiography (MRA) is regarded as one of the main
diagnostic modalities to assess peripheral artery disease.
Table 17 summarizes the recommendations for MRA to
assess peripheral artery disease.
Table 15 Recommendations for CMR in acute and chronic heart failure
Recommendations for CMR in ambulatory patients suspected of having heart failure Classa Levelb Page
CMR imaging is recommended to evaluate cardiac structure and function, to measure LVEF, and to characterize cardiac tissue,
especially in subjects with inadequate echocardiographic images or where the echocardiographic findings are inconclusive or
incomplete (but taking account of cautions/contraindications to CMR).
I C 10
Myocardial perfusion/ischaemia imaging (echocardiography, CMR, SPECT, or PET) should be considered in patients thought to
have coronary artery disease, and who are considered suitable for coronary revascularization, to determine whether there is
reversible myocardial ischaemia and viable myocardium.
IIa C 10
a Class of recommendation
b Level of evidence
Table 16 Recommendations for CMR during pregnancy
Recommendations Classa Levelb Page
CMR (without gadolinium) should be considered if echocardiography is insufficient for diagnosis. IIa C 14
Imaging of the entire aorta (CT/CMR) should be performed before pregnancy in patients with Marfan syndrome or other
known aortic disease.
I C 22
For imaging of pregnant women with dilatation of the distal ascending aorta, aortic arch or descending aorta, CMR (without
gadolinium) is recommended.
I C 22
a Class of recommendation
b Level of evidence
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2010 ESC guidelines for the management of grown-up
congenital heart disease [32]
CMR has become increasingly important in grown-up
with congenital heart disease (GUCH) and is an essential
facility in the specialist unit. ESC recommendations for
the use of CMR in GUCH patients have been published
separately [33]. There are several groups of indications
for CMR when assessing adult congenital heart disease
in clinical practice:
1. CMR as an alternative to echocardiography, when
both techniques can provide similar information but
echocardiography cannot be obtained with sufficient
quality.
2. CMR as a second method when
echocardiography measurements are borderline
or ambiguous.
3. Indications where CMR is considered superior to
echocardiography and should be regularly used
when the information is essential for patient
management. These indications include the
quantification of right ventricular (RV) volumes and
ejection fraction, RV and LV mass, evaluation of RV
outflow tract and conduits, quantification of
pulmonary regurgitation, evaluation of pulmonary
arteries, aorta, systemic and pulmonary veins,
collaterals and arteriovenous malformations,
coronary anomalies and coronary artery disease,
evaluation of intra- and extracardiac masses, and
myocardial tissue characterization (fibrosis, fat,
iron).
2010 focused update of ESC Guidelines on device therapy
in heart failure [34]
CMR is not mentioned in this guideline.
2009 guidelines for the diagnosis and management of
syncope [35]
In the diagnostic work-up of syncope, CMR - along with
other imaging modalities - may be performed in selected
cases (e.g. aortic dissection and haematoma, pulmonary
embolism, cardiac masses, pericardial and myocardial
diseases, congenital anomalies of coronary arteries)
(page 23).
Discussion
This is the first systematic summary of the representa-
tion of CMR in the ESC guidelines. It shows that CMR
is mentioned in the majority of guidelines (89 %) and
that more than 50 % of the guidelines contain specific
recommendations, when and how to use CMR. Al-
most all recommendations are in favour of the use of
CMR.
The majority of recommendations refer to stress im-
aging to assess coronary artery disease in general. Even
though CMR is not listed as the only recommended mo-
dality, it is ranked equally to nuclear studies and stress-
echocardiography. Recently, large and important studies
like CE-Marc have promoted this favourable position of
CMR [4]. Accordingly, the evaluation of suspected cor-
onary artery disease or ischemia in known coronary ar-
tery disease makes up the largest indication group for
CMR in the EuroCMR registry [2].
Interestingly, in the context of ischemic heart dis-
ease, the ESC guidelines are relatively conservative
in the evaluation of CMR viability testing. They rate
its ability to detect viability and predict recovery of
wall motion no better than with other imaging tech-
niques and do not word a specific recommendation
[16]. By way of contrast, viability testing makes up
Table 17 Recommendations for MRA to assess peripheral artery disease
Recommendations for evaluation of carotid artery stenosis Classa Levelb Page
Duplex ultrasound, CT-angiography, and/or MRA are indicated to evaluate carotid artery stenosis. I A 11
Recommendations for diagnosis of symptomatic chronic mesenteric ischaemia Classa Levelb Page
When Duplex ultrasound is inconclusive, CT-angiography or gadolinium-enhanced MRA are indicated. I B 19
Recommendations for diagnostic strategies for renal artery stenosis Classa Levelb Page
MRA (in patients with creatinine clearance >30 mL/min) is recommended to establish the diagnosis of renal artery stenosis. I B 21
Recommendations for diagnostic tests in patients with lower extremity artery disease Classa Levelb Page
Duplex ultrasound and/or CT-angiography and/or MRA are indicated to localize lower extremity artery disease lesions and
consider revascularization options.
I A 26
a Class of recommendation
b Level of evidence
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the third largest indication group in the EuroCMR
registry [2].
The use of CMR in HCM is also well represented in
the corresponding guideline. Thereby, CMR is mainly
recommended to describe the phenotype and make the
diagnosis, while its value for risk stratification for sud-
den cardiac death is still under debate [36]. Other car-
diomyopathies (e.g. DCM, ARVC) and myocarditis are
less well expressed in specific ESC recommendations.
This can be attributed to the lack of large-scale data, as
well as the absence of specific ESC-guidelines dedicated
to cardiomyopathies (other than HCM) or inflammatory
heart disease. The significance of CMR in these indica-
tion groups is underlined by several ESC position state-
ments: A recent document about myocarditis stated that
CMR may be considered in clinically stable patients
with myocarditis [37]. A recent document about car-
diomyopathies stated that the incremental contribu-
tion of CMR to the diagnosis of cardiomyopathies
derives from accurate assessment of the morphology
and function of the heart and tissue characterization [38].
Finally, a document about the role of endomyocardial bi-
opsy in the management of cardiovascular disease men-
tions CMR repeatedly as a valuable tool in patients
scheduled for biopsy either to assist or to replace biopsy
[39]. In those centers taking part in the EuroCMR registry,
cardiomyopathies and myocarditis make up the second
largest CMR indication group [2].
Other well-established indications for CMR are com-
pletely unmentioned in the ESC guidelines, like CMR in
the context of sarcoid disease. A recent consensus state-
ment by the Heart Rhythm Society from 2014 on the
diagnosis and management of arrhythmias associated
with cardiac sarcoid defined the presence of LGE on
CMR as one criteria for the diagnosis of cardiac sarcoid
[40]. Screening for cardiac involvement in patients with
biopsy-proven extracardiac sarcoidosis should include
advanced cardiac imaging like CMR under certain cir-
cumstances. Planning the ablation procedure based on
the predominant location of scarring as detected by
LGE-CMR may be helpful and CMR may support sud-
den death risk stratification. Nevertheless, for the
present analysis we decided to stick only to the ESC
guidelines to warrant a consistent level of guideline
standard.
Regarding valvular and congenital heart disease, the
ESC guidelines contain extensive text passages about the
value of CMR, reflecting current practice, where these
indications make up a substantial part of all
examinations [2]. In future guideline versions, the trans-
lation of these paragraphs into specific recommenda-
tions is needed to clarify the position of CMR.
This study touches several aspects: First, the fre-
quent representation of CMR in the ESC guidelines
demonstrates that the cardiology society has ac-
cepted CMR as an integral part of the armamentar-
ium of cardiovascular diagnostic modalities (e.g.
stress testing). As a next step, studies are needed
that analyse the adherence to the ESC guidelines and
how it impacts patients’ management [41]. Second,
there are several clinical scenarios, where CMR is
already used at dedicated centres, but which are not
well represented in the ESC guidelines (e.g. myocar-
ditis). Here, further studies are needed to provide
the required evidence. Third, CMR has not yet ar-
rived in the clinical reality in many regions of Eur-
ope. Hence, not everywhere in Europe can the
patients be managed according to the ESC guide-
lines. The reasons are certainly multifactorial, with
economic issues playing a central role: i) in some
diseases alternative techniques are often readily
available that provide similar information as CMR
does. This is especially true for testing for myocar-
dial ischemia, where SPECT and stress echocardiog-
raphy are still the dominant modalities. ii) CMR is
recognized as expensive and reimbursement not
aspired by the medical insurances in many countries. iii)
knowledge both to run a CMR examination and to inter-
pret the images with profound cardiologic knowledge is
often limited and structures for systematic training are
needed, including the establishment of cooperation be-
tween radiologists and cardiologists.
Already now, there are attempts how to overcome
the latter obstacles and to enable the use of CMR in
accordance with the guidelines: Recent large-scale
studies demonstrated the diagnostic accuracy of
CMR and its superiority in some indications [4];
prognostic data are available that demonstrate the
benefit of CMR [42]; there are studies that demon-
strate the potential for saving resources by using
CMR [43]; structures for acquiring CMR skills in-
cluding e-based learning are evolving [44]; and CMR
imaging became faster and the user interfaces easier
to handle.
Limitations of the study
This summary is not intended to provide a balanced
comparison of the various imaging modalities in the
ESC guidelines, but aimed at describing only the role of
CMR.
Conclusions
CMR is represented in the majority of the ESC guide-
lines. They contain many recommendations in favour of
the use of CMR in specific scenarios. Issues regarding
training, costs and reimbursement have to be solved to
provide CMR to the patients in accordance with the
ESC recommendations.
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Suspected/stable coronary artery disease Classa Levelb Guideline
Whenever history suggests myocardial ischaemia, a stress ECG test is recommended, and, if positive or ambiguous,
an imaging stress test (stress echocardiography, stress CMR or nuclear scintigraphy) is recommended.
I C [22]
In subjects with intermediate pretest probability for suspected coronary artery disease and stable symptoms,
stress CMR, stress-echo, SPECT or PET are recommended
I A [16]
In patients with suspected stable coronary artery disease and intermediate pretest probability of 15 % - 65 %
and LVEF =50 %, stress imaging is preferred as the initial test option if local expertise and availability permit.
I B [20]
An imaging stress test is recommended as the initial test for diagnosing stable coronary artery disease if the
pretest probability is between 66-85 % or if LVEF is <50 % in patients without typical angina.
I B [20]
An imaging stress test is recommended in patients with resting ECG abnormalities, which prevent accurate
interpretation of ECG changes during stress.
I B [20]
Stress imaging for risk stratification is recommended in patients with a non-conclusive exercise ECG I B [20]
Risk stratification is recommended based on clinical assessment and the results of the stress test initially
employed for making a diagnosis of stable coronary artery disease
I B [20]
In asymptomatic adults with diabetes or asymptomatic adults with a strong family history of coronary artery
disease or when previous risk assessment testing suggests high risk of coronary artery disease, such as a
coronary artery calcium score of 400 or greater stress imaging tests (MPI, stress echocardiography, perfusion
CMR) may be considered for advanced cardiovascular risk assessment.
IIb C [20]
In patients with stable coronary disease after a significant change in symptom level, risk stratification using
stress ECG (unless they cannot exercise or display ECG changes which make the ECG non evaluable) or
preferably stress imaging if local expertise and availability permit is recommended
I B [20]
In patients with known stable coronary artery disease and a deterioration in symptoms, stress imaging is
recommended for risk stratification if the site and extent of ischemia would influence clinical decision making
I B [20]
An exercise ECG or stress imaging if appropriate is recommended in the presence of recurrent or new symptoms
once instability has been ruled out.
I C [20]
Reassessment of the prognosis using stress testing may be considered in asymptomatic patients after the
expiration of the period for which the previous test was felt to be valid (“warranty period”)
IIb C [20]
Risk stratification before non-cardiac surgery Classa Levelb Guideline
Imaging stress testing is recommended before high-risk surgery in patients with more than two clinical risk factors
and poor functional capacity (<4 METs).
I C [18]
Imaging stress testing may be considered before high- or intermediate-risk surgery in patients with one or two
clinical risk factors and poor functional capacity (<4 METs).c
IIb C [18]
Imaging stress testing is not recommended before low-risk surgery, regardless of the patient’s clinical risk. III C [18]
Acute coronary syndrome Classa Levelb Guideline
In patients with no recurrence of chest pain, normal ECG findings and normal levels of cardiac troponin
(preferably high-sensitivity), but suspected acute coronary syndrome, a non-invasive stress test (preferably with
imaging) for inducible ischaemia is recommended before deciding on an invasive strategy.
I A [9]
If echocardiography is not feasible, CMR may be used as an alternative for assessment of infarct size and resting
LV function after STEMI.
IIb C [26]
For patients with multivessel disease, or in whom revascularization of other vessels is considered, stress testing
or imaging (e.g. using stress myocardial perfusion scintigraphy, stress echocardiography, positron emission
tomography or CMR) for ischaemia and viability is indicated after STEMI before or after discharge.
I A [26]
Before coronary revascularization Classa Levelb Guideline
An imaging stress test should be considered to assess the functional severity of intermediate lesions on coronary
arteriography.
IIa B [20]
To achieve a prognostic benefit by revascularization in patients with coronary artery disease, ischemia has to be
documented by non-invasive imaging
I A-C [16]
After coronary revascularization Classa Levelb Guideline
In asymptomatic patients after revascularisation, early imaging testing should be considered in specific patient
subsets.
IIa C [16]
Late (6 months) stress imaging test after revascularization may be considered to detect patients with restenosis
after stenting or graft occlusion irrespective of symptoms.
IIb C [20]
In asymptomatic patients, routine stress testing may be considered >2 years after PCI and >5 years after CABG. IIa B [16]
Appendix: Summary of clinical scenarios/diagnoses, where the ESC made recommendations regarding CMR
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(Continued)
In symptomatic patients with revascularized stable coronary artery disease, stress imaging (stress
echocardiography,
CMR or MPS) is indicated rather than stress ECG.
I C [20]
In symptomatic patients with prior revascularization (PCI or CABG), an imaging stress test should be considered IIa B [20]
In symptomatic patients after revascularization with low-risk findings at stress testing, it is recommended to
reinforce medical therapy and lifestyle changes.
I C [16]
In symptomatic patients after revascularization with intermediate- to high-risk findings at stress testing, coronary
angiography is recommended.
I C [16]
Heart failure Classa Levelb Guideline
CMR imaging is recommended to evaluate cardiac structure and function, to measure LVEF, and to characterize
cardiac tissue, especially in subjects with inadequate echocardiographic images or where the echocardiographic
findings are inconclusive or incomplete (but taking account of cautions/contraindications to CMR).
I C [27]
Myocardial perfusion/ischaemia imaging (echocardiography, CMR, SPECT, or PET) should be considered in patients
thought to have coronary artery disease, and who are considered suitable for coronary revascularization,
to determine whether there is reversible myocardial ischaemia and viable myocardium.
IIa C [27]
Ventricular arrhythmia Classa Levelb Guideline
Pharmacological stress testing plus imaging modality is recommended to detect silent ischaemia in patients
with ventricular arrhythmias who have an intermediate probability of having coronary artery disease by age or
symptoms and are physically unable to perform a symptom-limited exercise test.
I B [6]
CMR should be considered in patients with ventricular arrhythmias when echocardiography does not provide
accurate assessment of LV and RV function and/or evaluation of structural changes.
IIa B [6]
Inflammatory heart disease Classa Levelb Guideline
Demonstration of persistent myocardial inflammatory infiltrates by immunohistological evidence and/or
abnormal localized fibrosis by CMR after acute myocarditis may be considered as an additional indicator of
increased risk of SCD in inflammatory heart disease.
IIb C [6]
CMR is recommended for the confirmation of myocardial involvement in pericarditis I C [11]
Hypertrophic cardiomyopathy Classa Levelb Guideline
It is recommended that CMR studies in suspected HCM be performed and interpreted by teams experienced in
cardiac imaging and in the evaluation of heart muscle disease
I B [14]
In the absence of contraindications, CMR with LGE is recommended in patients with suspected HCM who have
inadequate echocardiographic windows, in order to confirm the diagnosis.
I C [14]
In the absence of contraindications, CMR with LGE should be considered in patients fulfilling diagnostic criteria
for HCM, to assess cardiac anatomy, ventricular function, and the presence and extent of myocardial fibrosis.
IIa B [14]
CMR with LGE imaging should be considered in patients with suspected apical hypertrophy or aneurysm. IIa C [14]
CMR with LGE may be considered before septal alcohol ablation or myectomy, to assess the extent and
distribution of hypertrophy and myocardial fibrosis.
IIb C [14]
CMR may be considered every 5 years in clinically stable patients, or every 2–3 years in patients with progressive
disease.
IIb C [14]
Athlete’s heart Classa Levelb Guideline
For prevention of sudden cardiac death in athletes, upon identification of ECG abnormalities suggestive of
structural heart disease, echocardiography and/or CMR imaging is recommended.
I C [6]
Storage disease Classa Levelb Guideline
CMR with LGE imaging should be considered in patients with suspected cardiac amyloidosis. IIa C [14]
Pericardial diseases Classa Levelb Guideline
CMR is second-level testing for diagnostic workup in pericarditis I C [11]
CMR should be considered in suspected cases of loculated pericardial effusion, pericardial thickening and masses,
as well as associated chest abnormalities
IIa C [11]
CMR is indicated as second-level imaging technique to assess pericardial thickness, degree and extension of
pericardial involvement for the diagnosis of constrictive pericarditis
I C [11]
Empiric anti-inflammatory therapy may be considered in cases with transient or new diagnosis of constrictive
pericarditis with concomitant evidence of pericardial inflammation (i.e. pericardial enhancement on CMR)
IIb C [11]
Pregnancy Classa Levelb Guideline
CMR (without gadolinium) should be considered if echocardiography is insufficient for diagnosis. IIa C [30]
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first days is recommended.
I C [15]
In uncomplicated Type B intramural hematoma, repetitive imaging (CMR or CT) is indicated. I C [15]
In uncomplicated Type B penetrating aortic ulcer, repetitive imaging (CMR or CT) is indicated. I C [15]
CMR or CT is indicated in patients with bicuspid aortic valve when the morphology of the aortic root and the
ascending aorta cannot be accurately assessed by TTE.
I C [15]
In the case of aortic diameter >50 mm or an increase >3 mm/year measured by echocardiography, confirmation
of the measurement is indicated, using another imaging modality (CT or CMR).
I C [15]
Contrast CT or CMR is recommended to confirm the diagnosis of chronic aortic dissection. I C [15]
For follow-up after (T)EVAR in young patients, CMR should be preferred to CT for magnetic resonance-compatible
stent grafts, to reduce radiation exposure.
IIa C [15]
CMR, CT, or digital subtraction angiography may be considered if carotid artery stenosis by ultrasound is >70 %
and myocardial revascularization is contemplated.
IIb C [16]
MR angiography should not be used to rule out pulmonary embolism. III C [17]
Duplex ultrasound, CT-angiography, and/or MRA are indicated to evaluate carotid artery stenosis. I A [31]
When Duplex ultrasound is inconclusive, CT-angiography or gadolinium-enhanced MRA are indicated to evaluate
chronic mesenteric ischaemia.
I B [31]
MRA (in patients with creatinine clearance >30 mL/min) is recommended to establish the diagnosis of renal
artery stenosis.
I B [31]
Duplex ultrasound and/or CT-angiography and/or MRA are indicated to localize lower extremity artery disease
lesions and consider revascularization options.
I A [31]
a Class of recommendation
b Level of evidence
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